LABELS · 2f0f60a5-832a-4954-ba26-7dec84fcf4f3

ARANESP

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2026-07-07
Captured: 2026-09-09T23:37:42.544548+00:00
Current indication reconciliation: Not reconciled

Boxed warning in this label

WARNING: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE Chronic Kidney Disease: In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis -stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL [ see Warnings and Precautions ( 5.1 )] . No trial has identified a hemoglobin target level, Aranesp dose, or dosing strategy that does not increase these risks [see Dosage and Administration ( 2.2 )] . Use the lowest Aranesp dose sufficient to reduce the need for red blood cell (RBC) transfusions [see Warnings and Precautions ( 5.1 )] . Cancer: ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in clinical studies of patients with breast, non- small cell lung, head and neck, lymphoid, and cervical cancers [ see Warnings and Precautions ( 5.2 )] . To decrease these risks, as well as the risk of serious cardiovascular and thromboembolic reactions, use the lowest dose needed to avoid RBC transfusions [see Dosage and Administration ( 2.3 )] . Use ESAs only for anemia from myelosuppressive chemotherapy [see Indications and Usage ( 1.2 )]. ESAs are not indicated for patients receiving myelosuppressive chemotherapy when the anticipated outcome is cure [see Indications and Usage ( 1.3 )]. Discontinue following the completion of a chemotherapy course [see Dosage and Administration ( 2.3 )] . WARNING: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE See full prescribing information for complete boxed warning. Chronic Kidney Disease : In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis - stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL ( 5.1 ). No trial has identified a hemoglobin target level, Aranesp dose, or dosing strategy that does not increase these risks ( 2.2 ) . Use the lowest Aranesp dose sufficient to reduce the need for red blood cell (RBC) transfusions ( 5.1 ). Cancer : ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in clinical studies of patients with breast, non - small cell lung, head and neck, lymphoid, and cervical cancers ( 5.2 ) . Use the lowest dose to avoid RBC transfusions ( 2.3 ) . Use ESAs only for anemia from myelosuppressive chemotherapy ( 1.2 ) . ESAs are not indicated for patients receiving myelosuppressive chemotherapy when the anticipated outcome is cure ( 1.3 ) . Discontinue following the completion of a chemotherapy course ( 2.3 ) .

Indications and usage: exact source text

1 INDICATIONS AND USAGE Aranesp is an erythropoiesis-stimulating agent (ESA) indicated for the treatment of anemia due to: Chronic Kidney Disease (CKD) in patients on dialysis and patients not on dialysis ( 1.1 ). The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy ( 1.2 ). Limitations of Use Aranesp has not been shown to improve quality of life, fatigue, or patient well-being ( 1.3 ). Aranesp is not indicated for use: In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy ( 1.3 ). In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure ( 1.3 ). In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion ( 1.3 ). As a substitute for RBC transfusions in patients who require immediate correction of anemia ( 1.3 ). 1.1 Anemia Due to Chronic Kidney Disease Aranesp is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and patients not on dialysis. 1.2 Anemia Due to Chemotherapy in Patients with Cancer Aranesp is indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy. 1.3 Limitations of Use Aranesp has not been shown to improve quality of life, fatigue, or patient well-being. Aranesp is not indicated for use: • In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy. • In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure. • In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion. • As a substitute for RBC transfusions in patients who require immediate correction of anemia.

Full extracted label fields

application numbers

BLA103951

boxed warning exact

WARNING: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE Chronic Kidney Disease: In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis -stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL [ see Warnings and Precautions ( 5.1 )] . No trial has identified a hemoglobin target level, Aranesp dose, or dosing strategy that does not increase these risks [see Dosage and Administration ( 2.2 )] . Use the lowest Aranesp dose sufficient to reduce the need for red blood cell (RBC) transfusions [see Warnings and Precautions ( 5.1 )] . Cancer: ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in clinical studies of patients with breast, non- small cell lung, head and neck, lymphoid, and cervical cancers [ see Warnings and Precautions ( 5.2 )] . To decrease these risks, as well as the risk of serious cardiovascular and thromboembolic reactions, use the lowest dose needed to avoid RBC transfusions [see Dosage and Administration ( 2.3 )] . Use ESAs only for anemia from myelosuppressive chemotherapy [see Indications and Usage ( 1.2 )]. ESAs are not indicated for patients receiving myelosuppressive chemotherapy when the anticipated outcome is cure [see Indications and Usage ( 1.3 )]. Discontinue following the completion of a chemotherapy course [see Dosage and Administration ( 2.3 )] . WARNING: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE See full prescribing information for complete boxed warning. Chronic Kidney Disease : In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis - stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL ( 5.1 ). No trial has identified a hemoglobin target level, Aranesp dose, or dosing strategy that does not increase these risks ( 2.2 ) . Use the lowest Aranesp dose sufficient to reduce the need for red blood cell (RBC) transfusions ( 5.1 ). Cancer : ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in clinical studies of patients with breast, non - small cell lung, head and neck, lymphoid, and cervical cancers ( 5.2 ) . Use the lowest dose to avoid RBC transfusions ( 2.3 ) . Use ESAs only for anemia from myelosuppressive chemotherapy ( 1.2 ) . ESAs are not indicated for patients receiving myelosuppressive chemotherapy when the anticipated outcome is cure ( 1.3 ) . Discontinue following the completion of a chemotherapy course ( 2.3 ) .

brand names

ARANESP

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0fd36cb9-c4f6-4167-93c9-8530865db3f9

generic names

DARBEPOETIN ALFA

2f0f60a5-832a-4954-ba26-7dec84fcf4f3

indications and usage exact

1 INDICATIONS AND USAGE Aranesp is an erythropoiesis-stimulating agent (ESA) indicated for the treatment of anemia due to: Chronic Kidney Disease (CKD) in patients on dialysis and patients not on dialysis ( 1.1 ). The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy ( 1.2 ). Limitations of Use Aranesp has not been shown to improve quality of life, fatigue, or patient well-being ( 1.3 ). Aranesp is not indicated for use: In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy ( 1.3 ). In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure ( 1.3 ). In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion ( 1.3 ). As a substitute for RBC transfusions in patients who require immediate correction of anemia ( 1.3 ). 1.1 Anemia Due to Chronic Kidney Disease Aranesp is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and patients not on dialysis. 1.2 Anemia Due to Chemotherapy in Patients with Cancer Aranesp is indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy. 1.3 Limitations of Use Aranesp has not been shown to improve quality of life, fatigue, or patient well-being. Aranesp is not indicated for use: • In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy. • In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure. • In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion. • As a substitute for RBC transfusions in patients who require immediate correction of anemia.

indications and usage tables exact

is original packager

true

manufacturer names

Amgen, Inc

matched search terms

cancer

package ndcs

55513-098-01
55513-098-04
55513-006-01
55513-006-21
55513-002-01
55513-002-04
55513-003-01
55513-003-04
55513-004-01
55513-004-04
55513-005-01
55513-005-04

product ndcs

55513-002
55513-098
55513-006
55513-003
55513-004
55513-005
55513-028
55513-111
55513-032
55513-057
55513-021
55513-023

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

INTRAVENOUS
SUBCUTANEOUS

rxcuis

349273
349274
349275
349276
352044
352045
352046
352047
730044
730046
731167
731171

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00100.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

BLA103951

brand names

ARANESP

classification reasons

explicit_positive_indication_predicate
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 413
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Aranesp is an erythropoiesis-stimulating agent (ESA) indicated for the treatment of anemia due to: Chronic Kidney Disease (CKD) in patients on dialysis and patients not on dialysis ( 1.1 ). The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy ( 1.2 ). Limitations of Use Aranesp has not been sho
label id: 2f0f60a5-832a-4954-ba26-7dec84fcf4f3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7be9a2880836a4aef30885249e66dfe19f108e3c5c04276e72de20fea8fa1a68
start: 0

current approval status

not_reconciled

duplicate text group

dup-40e8357ce56b1094f2e0

extraction review status

automated_candidate_pending_source_review

generic names

DARBEPOETIN ALFA

ind-span-dfcceccd2b628f1070c1

label id

2f0f60a5-832a-4954-ba26-7dec84fcf4f3

positive predicate support span

end: 86
end exclusive: true
exact text: is an erythropoiesis-stimulating agent (ESA) indicated
label id: 2f0f60a5-832a-4954-ba26-7dec84fcf4f3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7be9a2880836a4aef30885249e66dfe19f108e3c5c04276e72de20fea8fa1a68
start: 32

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 213
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Aranesp is an erythropoiesis-stimulating agent (ESA) indicated for the treatment of anemia due to: Chronic Kidney Disease (CKD) in patients on dialysis and patients not on dialysis ( 1.1 ).
label id: 2f0f60a5-832a-4954-ba26-7dec84fcf4f3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7be9a2880836a4aef30885249e66dfe19f108e3c5c04276e72de20fea8fa1a68
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%222f0f60a5-832a-4954-ba26-7dec84fcf4f3%22

spl effective date

2026-07-07

spl set id

0fd36cb9-c4f6-4167-93c9-8530865db3f9

spl version

161

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 2 · unclassified context

application numbers

BLA103951

brand names

ARANESP

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 569
end exclusive: true
exact text: AND USAGE Aranesp is an erythropoiesis-stimulating agent (ESA) indicated for the treatment of anemia due to: Chronic Kidney Disease (CKD) in patients on dialysis and patients not on dialysis ( 1.1 ). The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy ( 1.2 ). Limitations of Use Aranesp has not been shown to improve quality of life, fatigue, or patient well-being ( 1.3 ). Aranesp is not indicated for use: In patients with cancer receiving hormonal agents,
label id: 2f0f60a5-832a-4954-ba26-7dec84fcf4f3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7be9a2880836a4aef30885249e66dfe19f108e3c5c04276e72de20fea8fa1a68
start: 14

current approval status

not_reconciled

duplicate text group

dup-96dd72ee63e5bce3f0e3

extraction review status

automated_candidate_pending_source_review

generic names

DARBEPOETIN ALFA

ind-span-5252d81bbc25cdbfb75d

label id

2f0f60a5-832a-4954-ba26-7dec84fcf4f3

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 369
end exclusive: true
exact text: The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy ( 1.2 ).
label id: 2f0f60a5-832a-4954-ba26-7dec84fcf4f3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7be9a2880836a4aef30885249e66dfe19f108e3c5c04276e72de20fea8fa1a68
start: 214

source url

https://api.fda.gov/drug/label.json?search=id%3A%222f0f60a5-832a-4954-ba26-7dec84fcf4f3%22

spl effective date

2026-07-07

spl set id

0fd36cb9-c4f6-4167-93c9-8530865db3f9

spl version

161

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 3 · limitation of use

application numbers

BLA103951

brand names

ARANESP

classification reasons

limitation_heading

clinical review status

pending

content role

limitation_of_use

context span

end: 683
end exclusive: true
exact text: lysis and patients not on dialysis ( 1.1 ). The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy ( 1.2 ). Limitations of Use Aranesp has not been shown to improve quality of life, fatigue, or patient well-being ( 1.3 ). Aranesp is not indicated for use: In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy ( 1.3 ). In pa
label id: 2f0f60a5-832a-4954-ba26-7dec84fcf4f3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7be9a2880836a4aef30885249e66dfe19f108e3c5c04276e72de20fea8fa1a68
start: 170

current approval status

not_reconciled

duplicate text group

dup-06bcdb0dc7945bf2bafa

extraction review status

automated_candidate_pending_source_review

generic names

DARBEPOETIN ALFA

ind-span-edb108ee1de9db2be5ab

label id

2f0f60a5-832a-4954-ba26-7dec84fcf4f3

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 483
end exclusive: true
exact text: Limitations of Use Aranesp has not been shown to improve quality of life, fatigue, or patient well-being ( 1.3 ).
label id: 2f0f60a5-832a-4954-ba26-7dec84fcf4f3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7be9a2880836a4aef30885249e66dfe19f108e3c5c04276e72de20fea8fa1a68
start: 370

source url

https://api.fda.gov/drug/label.json?search=id%3A%222f0f60a5-832a-4954-ba26-7dec84fcf4f3%22

spl effective date

2026-07-07

spl set id

0fd36cb9-c4f6-4167-93c9-8530865db3f9

spl version

161

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 4 · limitation of use

application numbers

BLA103951

brand names

ARANESP

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 877
end exclusive: true
exact text: tiation, there is a minimum of two additional months of planned chemotherapy ( 1.2 ). Limitations of Use Aranesp has not been shown to improve quality of life, fatigue, or patient well-being ( 1.3 ). Aranesp is not indicated for use: In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy ( 1.3 ). In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure ( 1.3 ). In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be
label id: 2f0f60a5-832a-4954-ba26-7dec84fcf4f3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7be9a2880836a4aef30885249e66dfe19f108e3c5c04276e72de20fea8fa1a68
start: 284

current approval status

not_reconciled

duplicate text group

dup-3c19d26916d1b6397f8f

extraction review status

automated_candidate_pending_source_review

generic names

DARBEPOETIN ALFA

ind-span-d020eee2f3cc0302e904

label id

2f0f60a5-832a-4954-ba26-7dec84fcf4f3

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 677
end exclusive: true
exact text: Aranesp is not indicated for use: In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy ( 1.3 ).
label id: 2f0f60a5-832a-4954-ba26-7dec84fcf4f3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7be9a2880836a4aef30885249e66dfe19f108e3c5c04276e72de20fea8fa1a68
start: 484

source url

https://api.fda.gov/drug/label.json?search=id%3A%222f0f60a5-832a-4954-ba26-7dec84fcf4f3%22

spl effective date

2026-07-07

spl set id

0fd36cb9-c4f6-4167-93c9-8530865db3f9

spl version

161

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 5 · unclassified context

application numbers

BLA103951

brand names

ARANESP

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 987
end exclusive: true
exact text: .3 ). Aranesp is not indicated for use: In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy ( 1.3 ). In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure ( 1.3 ). In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion ( 1.3 ). As a substitute for RBC transfusions in patients who require immediate correc
label id: 2f0f60a5-832a-4954-ba26-7dec84fcf4f3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7be9a2880836a4aef30885249e66dfe19f108e3c5c04276e72de20fea8fa1a68
start: 478

current approval status

not_reconciled

duplicate text group

dup-2bd57eabbfcfc5845fbc

extraction review status

automated_candidate_pending_source_review

generic names

DARBEPOETIN ALFA

ind-span-1427004826e0ea405525

label id

2f0f60a5-832a-4954-ba26-7dec84fcf4f3

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 787
end exclusive: true
exact text: In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure ( 1.3 ).
label id: 2f0f60a5-832a-4954-ba26-7dec84fcf4f3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7be9a2880836a4aef30885249e66dfe19f108e3c5c04276e72de20fea8fa1a68
start: 678

source url

https://api.fda.gov/drug/label.json?search=id%3A%222f0f60a5-832a-4954-ba26-7dec84fcf4f3%22

spl effective date

2026-07-07

spl set id

0fd36cb9-c4f6-4167-93c9-8530865db3f9

spl version

161

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 6 · unclassified context

application numbers

BLA103951

brand names

ARANESP

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1109
end exclusive: true
exact text: or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy ( 1.3 ). In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure ( 1.3 ). In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion ( 1.3 ). As a substitute for RBC transfusions in patients who require immediate correction of anemia ( 1.3 ). 1.1 Anemia Due to Chronic Kidney Disease Aranesp is indicated for the treatment of anemia due to c
label id: 2f0f60a5-832a-4954-ba26-7dec84fcf4f3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7be9a2880836a4aef30885249e66dfe19f108e3c5c04276e72de20fea8fa1a68
start: 588

current approval status

not_reconciled

duplicate text group

dup-6a8cc5271be80b3bdb9d

extraction review status

automated_candidate_pending_source_review

generic names

DARBEPOETIN ALFA

ind-span-e708c8892446015a74a1

label id

2f0f60a5-832a-4954-ba26-7dec84fcf4f3

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 909
end exclusive: true
exact text: In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion ( 1.3 ).
label id: 2f0f60a5-832a-4954-ba26-7dec84fcf4f3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7be9a2880836a4aef30885249e66dfe19f108e3c5c04276e72de20fea8fa1a68
start: 788

source url

https://api.fda.gov/drug/label.json?search=id%3A%222f0f60a5-832a-4954-ba26-7dec84fcf4f3%22

spl effective date

2026-07-07

spl set id

0fd36cb9-c4f6-4167-93c9-8530865db3f9

spl version

161

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 7 · unclassified context

application numbers

BLA103951

brand names

ARANESP

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1210
end exclusive: true
exact text: g myelosuppressive chemotherapy when the anticipated outcome is cure ( 1.3 ). In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion ( 1.3 ). As a substitute for RBC transfusions in patients who require immediate correction of anemia ( 1.3 ). 1.1 Anemia Due to Chronic Kidney Disease Aranesp is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and patients not on dialysis. 1.2 Anemia
label id: 2f0f60a5-832a-4954-ba26-7dec84fcf4f3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7be9a2880836a4aef30885249e66dfe19f108e3c5c04276e72de20fea8fa1a68
start: 710

current approval status

not_reconciled

duplicate text group

dup-fe82e5b3f58264f5f8b5

extraction review status

automated_candidate_pending_source_review

generic names

DARBEPOETIN ALFA

ind-span-576e9e1520f1f2bd5e0e

label id

2f0f60a5-832a-4954-ba26-7dec84fcf4f3

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1010
end exclusive: true
exact text: As a substitute for RBC transfusions in patients who require immediate correction of anemia ( 1.3 ).
label id: 2f0f60a5-832a-4954-ba26-7dec84fcf4f3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7be9a2880836a4aef30885249e66dfe19f108e3c5c04276e72de20fea8fa1a68
start: 910

source url

https://api.fda.gov/drug/label.json?search=id%3A%222f0f60a5-832a-4954-ba26-7dec84fcf4f3%22

spl effective date

2026-07-07

spl set id

0fd36cb9-c4f6-4167-93c9-8530865db3f9

spl version

161

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 8 · positive indication candidate

application numbers

BLA103951

brand names

ARANESP

classification reasons

explicit_positive_indication_predicate
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1398
end exclusive: true
exact text: receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion ( 1.3 ). As a substitute for RBC transfusions in patients who require immediate correction of anemia ( 1.3 ). 1.1 Anemia Due to Chronic Kidney Disease Aranesp is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and patients not on dialysis. 1.2 Anemia Due to Chemotherapy in Patients with Cancer Aranesp is indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myel
label id: 2f0f60a5-832a-4954-ba26-7dec84fcf4f3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7be9a2880836a4aef30885249e66dfe19f108e3c5c04276e72de20fea8fa1a68
start: 811

current approval status

not_reconciled

duplicate text group

dup-fe5efe0289ebf5428367

extraction review status

automated_candidate_pending_source_review

generic names

DARBEPOETIN ALFA

ind-span-f58322167ba9fba8b921

label id

2f0f60a5-832a-4954-ba26-7dec84fcf4f3

positive predicate support span

end: 1072
end exclusive: true
exact text: is indicated
label id: 2f0f60a5-832a-4954-ba26-7dec84fcf4f3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7be9a2880836a4aef30885249e66dfe19f108e3c5c04276e72de20fea8fa1a68
start: 1060

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1198
end exclusive: true
exact text: 1.1 Anemia Due to Chronic Kidney Disease Aranesp is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and patients not on dialysis.
label id: 2f0f60a5-832a-4954-ba26-7dec84fcf4f3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7be9a2880836a4aef30885249e66dfe19f108e3c5c04276e72de20fea8fa1a68
start: 1011

source url

https://api.fda.gov/drug/label.json?search=id%3A%222f0f60a5-832a-4954-ba26-7dec84fcf4f3%22

spl effective date

2026-07-07

spl set id

0fd36cb9-c4f6-4167-93c9-8530865db3f9

spl version

161

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 9 · positive indication candidate

application numbers

BLA103951

brand names

ARANESP

classification reasons

explicit_positive_indication_predicate
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1714
end exclusive: true
exact text: ia ( 1.3 ). 1.1 Anemia Due to Chronic Kidney Disease Aranesp is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and patients not on dialysis. 1.2 Anemia Due to Chemotherapy in Patients with Cancer Aranesp is indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy. 1.3 Limitations of Use Aranesp has not been shown to improve quality of life, fatigue, or patient well-being. Aranesp is not indicated for use: • In patients with cancer receiving hormonal agents, bi
label id: 2f0f60a5-832a-4954-ba26-7dec84fcf4f3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7be9a2880836a4aef30885249e66dfe19f108e3c5c04276e72de20fea8fa1a68
start: 999

current approval status

not_reconciled

duplicate text group

dup-3ce386b6a43321023966

extraction review status

automated_candidate_pending_source_review

generic names

DARBEPOETIN ALFA

ind-span-3c64fe893b1e89b09b9a

label id

2f0f60a5-832a-4954-ba26-7dec84fcf4f3

positive predicate support span

end: 1274
end exclusive: true
exact text: is indicated
label id: 2f0f60a5-832a-4954-ba26-7dec84fcf4f3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7be9a2880836a4aef30885249e66dfe19f108e3c5c04276e72de20fea8fa1a68
start: 1262

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1514
end exclusive: true
exact text: 1.2 Anemia Due to Chemotherapy in Patients with Cancer Aranesp is indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy.
label id: 2f0f60a5-832a-4954-ba26-7dec84fcf4f3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7be9a2880836a4aef30885249e66dfe19f108e3c5c04276e72de20fea8fa1a68
start: 1199

source url

https://api.fda.gov/drug/label.json?search=id%3A%222f0f60a5-832a-4954-ba26-7dec84fcf4f3%22

spl effective date

2026-07-07

spl set id

0fd36cb9-c4f6-4167-93c9-8530865db3f9

spl version

161

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 10 · limitation of use

application numbers

BLA103951

brand names

ARANESP

classification reasons

limitation_heading

clinical review status

pending

content role

limitation_of_use

context span

end: 1824
end exclusive: true
exact text: with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy. 1.3 Limitations of Use Aranesp has not been shown to improve quality of life, fatigue, or patient well-being. Aranesp is not indicated for use: • In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy. • In patien
label id: 2f0f60a5-832a-4954-ba26-7dec84fcf4f3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7be9a2880836a4aef30885249e66dfe19f108e3c5c04276e72de20fea8fa1a68
start: 1315

current approval status

not_reconciled

duplicate text group

dup-27205f63e6b418d00726

extraction review status

automated_candidate_pending_source_review

generic names

DARBEPOETIN ALFA

ind-span-28baf4df89cccc0c9aad

label id

2f0f60a5-832a-4954-ba26-7dec84fcf4f3

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1624
end exclusive: true
exact text: 1.3 Limitations of Use Aranesp has not been shown to improve quality of life, fatigue, or patient well-being.
label id: 2f0f60a5-832a-4954-ba26-7dec84fcf4f3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7be9a2880836a4aef30885249e66dfe19f108e3c5c04276e72de20fea8fa1a68
start: 1515

source url

https://api.fda.gov/drug/label.json?search=id%3A%222f0f60a5-832a-4954-ba26-7dec84fcf4f3%22

spl effective date

2026-07-07

spl set id

0fd36cb9-c4f6-4167-93c9-8530865db3f9

spl version

161

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 11 · limitation of use

application numbers

BLA103951

brand names

ARANESP

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 1858
end exclusive: true
exact text: and upon initiation, there is a minimum of two additional months of planned chemotherapy. 1.3 Limitations of Use Aranesp has not been shown to improve quality of life, fatigue, or patient well-being. Aranesp is not indicated for use: • In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy. • In patients with cancer receiving myelosupp
label id: 2f0f60a5-832a-4954-ba26-7dec84fcf4f3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7be9a2880836a4aef30885249e66dfe19f108e3c5c04276e72de20fea8fa1a68
start: 1425

current approval status

not_reconciled

duplicate text group

dup-d6e5f53aab1c6a1e63a9

extraction review status

automated_candidate_pending_source_review

generic names

DARBEPOETIN ALFA

ind-span-1116f1b1f6cdbd140e64

label id

2f0f60a5-832a-4954-ba26-7dec84fcf4f3

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1658
end exclusive: true
exact text: Aranesp is not indicated for use:
label id: 2f0f60a5-832a-4954-ba26-7dec84fcf4f3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7be9a2880836a4aef30885249e66dfe19f108e3c5c04276e72de20fea8fa1a68
start: 1625

source url

https://api.fda.gov/drug/label.json?search=id%3A%222f0f60a5-832a-4954-ba26-7dec84fcf4f3%22

spl effective date

2026-07-07

spl set id

0fd36cb9-c4f6-4167-93c9-8530865db3f9

spl version

161

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 12 · unclassified context

application numbers

BLA103951

brand names

ARANESP

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2012
end exclusive: true
exact text: nimum of two additional months of planned chemotherapy. 1.3 Limitations of Use Aranesp has not been shown to improve quality of life, fatigue, or patient well-being. Aranesp is not indicated for use: • In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy. • In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure. • In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be man
label id: 2f0f60a5-832a-4954-ba26-7dec84fcf4f3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7be9a2880836a4aef30885249e66dfe19f108e3c5c04276e72de20fea8fa1a68
start: 1459

current approval status

not_reconciled

duplicate text group

dup-f8688c7eff0a5b85d600

extraction review status

automated_candidate_pending_source_review

generic names

DARBEPOETIN ALFA

ind-span-bb6931c1ed30cc910028

label id

2f0f60a5-832a-4954-ba26-7dec84fcf4f3

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1812
end exclusive: true
exact text: • In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy.
label id: 2f0f60a5-832a-4954-ba26-7dec84fcf4f3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7be9a2880836a4aef30885249e66dfe19f108e3c5c04276e72de20fea8fa1a68
start: 1659

source url

https://api.fda.gov/drug/label.json?search=id%3A%222f0f60a5-832a-4954-ba26-7dec84fcf4f3%22

spl effective date

2026-07-07

spl set id

0fd36cb9-c4f6-4167-93c9-8530865db3f9

spl version

161

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 13 · unclassified context

application numbers

BLA103951

brand names

ARANESP

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2116
end exclusive: true
exact text: well-being. Aranesp is not indicated for use: • In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy. • In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure. • In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion. • As a substitute for RBC transfusions in patients who require immediate correction
label id: 2f0f60a5-832a-4954-ba26-7dec84fcf4f3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7be9a2880836a4aef30885249e66dfe19f108e3c5c04276e72de20fea8fa1a68
start: 1613

current approval status

not_reconciled

duplicate text group

dup-182e01e384d818338e66

extraction review status

automated_candidate_pending_source_review

generic names

DARBEPOETIN ALFA

ind-span-61a7ddec91cbc455a9fc

label id

2f0f60a5-832a-4954-ba26-7dec84fcf4f3

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1916
end exclusive: true
exact text: • In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure.
label id: 2f0f60a5-832a-4954-ba26-7dec84fcf4f3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7be9a2880836a4aef30885249e66dfe19f108e3c5c04276e72de20fea8fa1a68
start: 1813

source url

https://api.fda.gov/drug/label.json?search=id%3A%222f0f60a5-832a-4954-ba26-7dec84fcf4f3%22

spl effective date

2026-07-07

spl set id

0fd36cb9-c4f6-4167-93c9-8530865db3f9

spl version

161

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 14 · unclassified context

application numbers

BLA103951

brand names

ARANESP

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2127
end exclusive: true
exact text: gic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy. • In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure. • In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion. • As a substitute for RBC transfusions in patients who require immediate correction of anemia.
label id: 2f0f60a5-832a-4954-ba26-7dec84fcf4f3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7be9a2880836a4aef30885249e66dfe19f108e3c5c04276e72de20fea8fa1a68
start: 1717

current approval status

not_reconciled

duplicate text group

dup-efda67ad71ca694e2529

extraction review status

automated_candidate_pending_source_review

generic names

DARBEPOETIN ALFA

ind-span-c5780a9c3c907ef680b2

label id

2f0f60a5-832a-4954-ba26-7dec84fcf4f3

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 2032
end exclusive: true
exact text: • In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion.
label id: 2f0f60a5-832a-4954-ba26-7dec84fcf4f3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7be9a2880836a4aef30885249e66dfe19f108e3c5c04276e72de20fea8fa1a68
start: 1917

source url

https://api.fda.gov/drug/label.json?search=id%3A%222f0f60a5-832a-4954-ba26-7dec84fcf4f3%22

spl effective date

2026-07-07

spl set id

0fd36cb9-c4f6-4167-93c9-8530865db3f9

spl version

161

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 15 · unclassified context

application numbers

BLA103951

brand names

ARANESP

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2127
end exclusive: true
exact text: ancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure. • In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion. • As a substitute for RBC transfusions in patients who require immediate correction of anemia.
label id: 2f0f60a5-832a-4954-ba26-7dec84fcf4f3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7be9a2880836a4aef30885249e66dfe19f108e3c5c04276e72de20fea8fa1a68
start: 1833

current approval status

not_reconciled

duplicate text group

dup-57e65ec886e670f36c01

extraction review status

automated_candidate_pending_source_review

generic names

DARBEPOETIN ALFA

ind-span-a998afa07b43bee051b3

label id

2f0f60a5-832a-4954-ba26-7dec84fcf4f3

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 2127
end exclusive: true
exact text: • As a substitute for RBC transfusions in patients who require immediate correction of anemia.
label id: 2f0f60a5-832a-4954-ba26-7dec84fcf4f3
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7be9a2880836a4aef30885249e66dfe19f108e3c5c04276e72de20fea8fa1a68
start: 2033

source url

https://api.fda.gov/drug/label.json?search=id%3A%222f0f60a5-832a-4954-ba26-7dec84fcf4f3%22

spl effective date

2026-07-07

spl set id

0fd36cb9-c4f6-4167-93c9-8530865db3f9

spl version

161

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Preserved source evidence · Not medical advice